Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Mazdutide

Investigational

GLP-1/glucagon dual agonist

Also known as: IBI362, IBI-362, GLXC-26803, LY-3305677

Evidence score

65/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 43 registered studies on ClinicalTrials.gov, most advanced Phase 4
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Mazdutide (also coded LY3305677 and IBI362) is a synthetic peptide that activates both the GLP-1 receptor and the glucagon receptor. GLP-1 signaling is linked to appetite reduction and blood sugar control, while glucagon receptor activity is thought to increase energy expenditure and affect liver fat. It was originally developed by Eli Lilly and advanced clinically by Innovent Biologics.

What the evidence shows

Automatic summaryLimited human data

It is not FDA-approved and remains investigational in the US. There is a substantial human trial record, with 43 registered trials and Phase 3 studies reporting weight loss and improved blood sugar in adults with obesity or type 2 diabetes, but long-term safety and outcome data are still limited.

Key facts

Molecular formula

C207H317N45O65

Molecular weight

4476 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

43registered studies

Phase 4most advanced phase

18completed (sample)

9recruiting (sample)

A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase 2Active Not RecruitingNCT06937749

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Phase 2CompletedNCT06817356

Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

Phase 4RecruitingNCT07657676

A Study of IBI362 9 mg in Chinese Adults With Obesity

Phase 3UnknownNCT06164873

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

62papers referencing Mazdutide

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

N Engl J Med2025

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

Nat Commun2023

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

EClinicalMedicine2022

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Diabetes Care2024

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.